Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K022693
    Date Cleared
    2002-12-09

    (118 days)

    Product Code
    Regulation Number
    862.3910
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    INSTANT-VIEW TCA URINE TEST

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    This device is a one-step immunoassay intended to provide qualitative rapid detection of tricyclic antidepressants (TCA) at a cutoff level of 1000 ng/ml in human urine. It is for health care professional use only.

    It is for health care professional, in-vitro diagnostic use only.

    This device is a one-step immunoassay intended to provide qualitative rapid detection of tricyclic antidepressants (TCA) at a cutoff concentration of 1,000 ng/ml in human urine. It is for health care professional use only.

    Instant-View™ TCA Urine Test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

    Device Description

    A one-step lateral flow chromatographic immunoassay. The test strip in the device includes 1) a conjugate pad containing colloidal gold coupled with mouse anti-TCA antibodies; 2) nitrocellulose membrane containing a test line (T line) and a control line (C line). The Test line is coated with TCA- BSA, and the Control line is coated with goat anti-mouse IgG antibody.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study information for the Instant-View™ TCA Urine Test, based on the provided 510(k) summary:

    1. Table of Acceptance Criteria and Reported Device Performance

    Acceptance Criteria CategoryAcceptance Criteria (Implicit)Reported Device Performance
    Accuracy - NegativeHigh agreement with GC/MS for negative samples96.7% (58/60) agreement
    Accuracy - PositiveHigh agreement with GC/MS for positive samples100% (20/20) agreement
    Accuracy - OverallHigh overall agreement with GC/MS97.5% overall accuracy
    ReproducibilityHigh agreement across different testing sites and operators99% agreement across four sites
    Specificity - Related CompoundsPositive response to TCA-related compounds at or above cutoffPositive responses to Amitriptyline, Desipramine, Imipramine, Nortriptyline, Nordoxepine at 1000 ng/ml; Cyclobenzaprine, Protriptyline, Trimipramine > 1500 ng/ml; Doxepine, Clomipramine > 3000 ng/ml.
    Specificity - Unrelated CompoundsNo significant interference from structurally unrelated compoundsNo significant interference observed with structurally unrelated compounds at 1 mg/ml.

    Note: The acceptance criteria are implicit based on the reported performance. The document doesn't explicitly state quantitative thresholds the device needed to meet, but rather presents the results as demonstrating "accuracy," "reproducibility," and "specificity."

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size for Accuracy Test Set: 80 clinical urine samples.
    • Data Provenance: The document states "clinical urine samples," which implies human-derived samples. There is no information provided regarding the country of origin of the data or whether it was retrospective or prospective.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

    The ground truth for the accuracy study was established by GC/MS (Gas Chromatography/Mass Spectrometry), which is a chemical method, not human expert interpretation. Therefore, the concept of "number of experts" and "qualifications of experts" as typically applied to imaging or diagnostic interpretation by trained professionals does not directly apply here. GC/MS itself is considered a gold standard for drug quantification.

    4. Adjudication Method for the Test Set

    Not applicable. The ground truth was established by GC/MS, a definitive chemical analysis method, not by human adjudication of potentially subjective interpretations.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    No. This study is for an in vitro diagnostic device (immunoassay) for drug detection, not an AI-assisted diagnostic tool that would involve human readers interpreting cases. Therefore, an MRMC comparative effectiveness study is not relevant here.

    6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study

    Yes, the accuracy and reproducibility studies described are standalone performance evaluations of the device itself (the immunoassay) without human interpretation being part of the primary outcome measure. While humans operate the test and interpret its visual output (lines on a strip), the core performance metrics are determined by how accurately the device differentiates between samples at the cutoff compared to the GC/MS reference.

    7. Type of Ground Truth Used

    The ground truth used was GC/MS (Gas Chromatography/Mass Spectrometry), which is a highly specific and quantitative analytical method, often considered a definitive or "gold standard" for confirming the presence and concentration of drugs.

    8. Sample Size for the Training Set

    No information is provided regarding a "training set." This device is a lateral flow immunoassay, not a machine learning or AI algorithm that typically requires a distinct training set. The performance is based on its inherent biochemical reactivity and design.

    9. How the Ground Truth for the Training Set Was Established

    Not applicable, as there is no mention or indication of a training set for this type of device.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1